Wedbush initiated coverage of Ovid Therapeutics with an Outperform rating and $8 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Marinus Comments on patent challenge by Ovid Therapeutics
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
- Ovid Therapeutics reports Q4 EPS (22c), consensus (5c)
- Ovid Therapeutics management to meet with Oppenheimer
- Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference